RU2629768C2 - Гуманизированные антитела к ctla4 - Google Patents

Гуманизированные антитела к ctla4 Download PDF

Info

Publication number
RU2629768C2
RU2629768C2 RU2013145243A RU2013145243A RU2629768C2 RU 2629768 C2 RU2629768 C2 RU 2629768C2 RU 2013145243 A RU2013145243 A RU 2013145243A RU 2013145243 A RU2013145243 A RU 2013145243A RU 2629768 C2 RU2629768 C2 RU 2629768C2
Authority
RU
Russia
Prior art keywords
ctla4
antibody
human
seq
antibodies
Prior art date
Application number
RU2013145243A
Other languages
English (en)
Russian (ru)
Other versions
RU2013145243A (ru
Inventor
Тимоти Дэвид ДЖОНС
Роберт Джордж Эдвард ХОЛГЕЙТ
Френсис Джозеф КАРР
Original Assignee
Антитоуп Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Антитоуп Лтд filed Critical Антитоуп Лтд
Publication of RU2013145243A publication Critical patent/RU2013145243A/ru
Application granted granted Critical
Publication of RU2629768C2 publication Critical patent/RU2629768C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
RU2013145243A 2011-03-09 2012-03-09 Гуманизированные антитела к ctla4 RU2629768C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161450896P 2011-03-09 2011-03-09
GB1103955.9 2011-03-09
US61/450,896 2011-03-09
GBGB1103955.9A GB201103955D0 (en) 2011-03-09 2011-03-09 Antibodies
PCT/EP2012/054144 WO2012120125A1 (en) 2011-03-09 2012-03-09 Humanised anti ctla-4 antibodies

Publications (2)

Publication Number Publication Date
RU2013145243A RU2013145243A (ru) 2015-04-20
RU2629768C2 true RU2629768C2 (ru) 2017-09-06

Family

ID=43923406

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013145243A RU2629768C2 (ru) 2011-03-09 2012-03-09 Гуманизированные антитела к ctla4

Country Status (18)

Country Link
US (1) US9714290B2 (OSRAM)
EP (1) EP2683739B1 (OSRAM)
JP (1) JP6211930B2 (OSRAM)
KR (1) KR20140033013A (OSRAM)
CN (1) CN103547595B (OSRAM)
AU (1) AU2012224511B2 (OSRAM)
BR (1) BR112013022797A2 (OSRAM)
CA (1) CA2828528C (OSRAM)
DK (1) DK2683739T3 (OSRAM)
ES (1) ES2571129T3 (OSRAM)
GB (1) GB201103955D0 (OSRAM)
IL (1) IL228203A (OSRAM)
MX (1) MX344971B (OSRAM)
MY (1) MY166776A (OSRAM)
RU (1) RU2629768C2 (OSRAM)
SG (1) SG192969A1 (OSRAM)
WO (1) WO2012120125A1 (OSRAM)
ZA (1) ZA201306589B (OSRAM)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2860170C (en) 2010-12-22 2022-06-14 The Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
EP4011913A1 (en) 2011-06-30 2022-06-15 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
WO2014149067A1 (en) * 2013-03-15 2014-09-25 Momenta Pharmaceuticals, Inc. Methods related to ctla4-fc fusion proteins
EP2996772B1 (en) 2013-05-13 2018-12-19 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
EP3995507B1 (en) 2013-08-08 2023-10-04 Cytune Pharma Il-15 and il-15ralpha sushi domain based on modulokines
LT3030262T (lt) 2013-08-08 2020-03-10 Cytune Pharma Kombinuota farmacinė kompozicija
CA2925421C (en) 2013-09-24 2023-08-29 Medicenna Therapeutics, Inc. Interleukin-2 fusion proteins and uses thereof
WO2015057622A1 (en) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
SG10201805674YA (en) * 2014-01-02 2018-08-30 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
CN105296433B (zh) * 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
US20170224777A1 (en) 2014-08-12 2017-08-10 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
EP3180018B1 (en) 2014-08-12 2019-07-24 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
IL251669B2 (en) 2014-10-10 2023-02-01 Idera Pharmaceuticals Inc Cancer treatment using a tlr9 agonist with checkpoint inhibitors
WO2016127052A1 (en) 2015-02-05 2016-08-11 Bristol-Myers Squibb Company Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
WO2016130986A1 (en) * 2015-02-13 2016-08-18 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
US10806787B2 (en) 2015-02-16 2020-10-20 Pharma Foods International Co., Ltd. Anticancer agents or antimetastatic agents using FSTL1 and combination drug thereof
SI3303394T1 (sl) * 2015-05-29 2020-10-30 Agenus Inc. Protitelesa proti-CTLA-4 in postopki njihove uporabe
NL2014935B1 (en) * 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
NZ739503A (en) 2015-07-16 2023-06-30 Bioxcel Therapeutics Inc A novel approach for treatment of cancer using immunomodulation
CN107949573B (zh) 2015-09-01 2022-05-03 艾吉纳斯公司 抗-pd-1抗体及其使用方法
WO2017084078A1 (en) * 2015-11-19 2017-05-26 Zeling Cai Ctla-4 antibodies and uses thereof
US10954301B2 (en) 2015-12-14 2021-03-23 Macrogenics, Inc. Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
SG11201804969PA (en) * 2015-12-15 2018-07-30 Oncoimmune Inc Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
EP3400023A1 (en) 2016-01-10 2018-11-14 ModernaTX, Inc. Therapeutic mrnas encoding anti ctla-4 antibodies
BR112018068461A2 (pt) 2016-03-15 2019-01-22 Mersana Therapeutics Inc conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer.
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
WO2017165778A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
EA039322B1 (ru) * 2016-04-15 2022-01-13 Эйдженус Инк. Антитела против ctla-4 и способы их применения
MA45037A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polythérapie à base d'arnm pour le traitement du cancer
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
WO2018006005A1 (en) 2016-06-30 2018-01-04 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides
KR20190086431A (ko) * 2016-08-17 2019-07-22 오르비스 헬스 솔루션즈 엘엘씨 종양-표적화 비드 벡터 및 그의 사용 방법
CN106967172B (zh) 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
CN106977602B (zh) 2016-08-23 2018-09-25 中山康方生物医药有限公司 一种抗pd1单克隆抗体、其药物组合物及其用途
WO2018035710A1 (en) * 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
CN107815467B (zh) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
CN107815468B (zh) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
WO2018041121A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric ctla-4
KR102576042B1 (ko) 2016-10-11 2023-09-07 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
IL266918B2 (en) 2016-12-07 2024-03-01 Agenus Inc Anti-ctla-4 antibodies and methods of use thereof
WO2018112266A1 (en) 2016-12-14 2018-06-21 The Board Of Trustees Of The Leland Stanford Junior University Il-13 superkine: immune cell targeting constructs and methods of use thereof
WO2018132516A1 (en) 2017-01-10 2018-07-19 Nodus Therapeutics Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
EP3585430A4 (en) * 2017-02-21 2020-12-09 REMD Biotherapeutics, Inc. TREATMENT OF CANCER WITH ANTIBODIES THAT BIND TO T-CYTOTOXIC T-LYMPHOCYTES ANTIGEN-4 (CTLA-4)
WO2018160538A1 (en) 2017-02-28 2018-09-07 Mersana Therapeutics, Inc. Combination therapies of her2-targeted antibody-drug conjugates
US20190382490A1 (en) * 2017-02-28 2019-12-19 Bristol-Myers Squibb Company Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
CN108124445B (zh) * 2017-03-15 2021-05-04 苏州银河生物医药有限公司 Ctla4抗体、其药物组合物及其用途
CN108948194B (zh) * 2017-05-19 2023-02-17 上海药明生物技术有限公司 一种新的ctla-4单克隆抗体
KR102372274B1 (ko) 2017-05-19 2022-03-08 우시 바이올로직스 (상하이) 컴퍼니 리미티드 세포독성 t-림프구-관련 단백질 4 (ctla-4)에 대한 신규의 단일클론 항체
US11542312B2 (en) 2017-06-19 2023-01-03 Medicenna Therapeutics, Inc. IL-2 superagonists in combination with anti-PD-1 antibodies
TWI799432B (zh) * 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
WO2019020807A1 (en) * 2017-07-28 2019-01-31 Gene Signal International Sa CD9P-1 TARGETING ANTIBODIES AND USES THEREOF
US20200172618A1 (en) * 2017-07-28 2020-06-04 Gene Signal International Sa Cd9p-1-targeting antibody and uses thereof
CA3073984A1 (en) * 2017-09-21 2019-03-28 Eucure (Beijing) Biopharma Co., Ltd Anti-ctla4 antibodies and uses thereof
WO2019104289A1 (en) 2017-11-27 2019-05-31 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
IL275391B2 (en) 2017-12-20 2025-05-01 Harbour Biomed Shanghai Co Ltd Antibodies binding ctla-4 and uses thereof
JP2021506883A (ja) 2017-12-21 2021-02-22 メルサナ セラピューティクス インコーポレイテッド ピロロベンゾジアゼピン抗体結合体
US11865081B2 (en) 2017-12-29 2024-01-09 Virogin Biotech Canada Ltd. Oncolytic viral delivery of therapeutic polypeptides
CA3102097A1 (en) 2018-06-01 2019-12-05 The Board Of Trustees Of The Leland Stanford Junior Unversity Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
CN112638375A (zh) 2018-06-15 2021-04-09 旗舰创业创新五公司 通过后细胞信号传导因子的调节来增加免疫活性
JP2021530243A (ja) 2018-07-25 2021-11-11 アスクジーン・ファーマ・インコーポレイテッドAskGene Pharma, Inc. 新規ｉｌ−２１プロドラッグおよびそれを使用する方法
CN110760002A (zh) * 2018-07-25 2020-02-07 南京金斯瑞生物科技有限公司 人源化抗人ctla4单克隆抗体及其制备方法和用途
JP7407822B2 (ja) 2018-08-30 2024-01-04 エイチシーダブリュー バイオロジックス インコーポレイテッド 単鎖キメラポリペプチドおよびその使用
AU2019328575B2 (en) 2018-08-30 2024-07-11 Immunitybio, Inc. Single-chain and multi-chain chimeric polypeptides and uses thereof
CA3108949A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
EP3856763A1 (en) 2018-09-28 2021-08-04 Massachusetts Institute of Technology Collagen-localized immunomodulatory molecules and methods thereof
EP3873534A1 (en) 2018-10-29 2021-09-08 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
IL291545B1 (en) * 2018-10-31 2025-09-01 Bioatla Llc Anti-CTLA4 antibodies, antibody fragments, immunoconjugates thereof and uses thereof
CN113614109A (zh) 2018-12-21 2021-11-05 Ose免疫疗法公司 双功能抗pd-1/il-7分子
CA3123050A1 (en) 2018-12-26 2020-07-02 City Of Hope Activatable masked anti-ctla4 binding proteins
CN119930820A (zh) * 2018-12-27 2025-05-06 吉加根公司 抗ctla-4结合蛋白及其使用方法
US11235032B2 (en) 2019-01-23 2022-02-01 Massachusetts Institute Of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
TWI869398B (zh) * 2019-05-10 2025-01-11 英商拜西克爾德有限公司 治療癌症之方法
WO2020252264A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
WO2020257639A1 (en) 2019-06-21 2020-12-24 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
EP3990491A1 (en) 2019-06-26 2022-05-04 Massachusetts Institute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
CN114174336B (zh) * 2019-07-15 2024-10-11 英特维特国际股份有限公司 针对人和犬ctla-4的犬源化抗体
US12435143B2 (en) 2019-07-15 2025-10-07 Intervet Inc. Caninized antibodies against canine CTLA-4
CN110467675B (zh) * 2019-09-19 2020-08-14 合源生物科技(天津)有限公司 一种ctla-4单克隆抗体6f1及其用于抗肿瘤的用途
US11459389B2 (en) 2019-10-24 2022-10-04 Massachusetts Institute Of Technology Monoclonal antibodies that bind human CD161
WO2021127217A1 (en) 2019-12-17 2021-06-24 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
WO2021122866A1 (en) 2019-12-17 2021-06-24 Ose Immunotherapeutics Bifunctional molecules comprising an il-7 variant
UA128549C2 (uk) 2019-12-27 2024-08-07 Чугаі Сейяку Кабусікі Кайся Антитіло до ctla-4 та його застосування
US12187763B2 (en) 2020-02-11 2025-01-07 Immunitybio, Inc. Chromatography resin and uses thereof
WO2021163369A2 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of treating age-related and inflammatory diseases
CA3169243A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of activating regulatory t cells
US20230149560A1 (en) 2020-04-20 2023-05-18 Massachusetts Institute Of Technology Lipid compositions for delivery of sting agonist compounds and uses thereof
US12159700B2 (en) 2020-04-22 2024-12-03 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
JP7734693B2 (ja) 2020-04-29 2025-09-05 イミュニティーバイオ インコーポレイテッド 抗ｃｄ２６タンパク質及びそれらの使用法
IL298608A (en) 2020-06-01 2023-01-01 Hcw Biologics Inc Methods of treating aging-related disorders
WO2021247003A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
CA3186777A1 (en) * 2020-06-11 2021-12-16 Nantbio, Inc. Anti-ctla4 monoclonal antibodies and chimeric antigen receptors
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
MX2022015948A (es) * 2020-07-02 2023-04-05 Gigagen Inc Proteínas de unión anti-ctla-4 y métodos de uso de estas.
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
WO2022169269A1 (ko) * 2021-02-03 2022-08-11 주식회사 유틸렉스 항 ctla-4 항체 및 이의 용도
KR20230165276A (ko) 2021-03-31 2023-12-05 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도
WO2022214653A1 (en) 2021-04-09 2022-10-13 Ose Immunotherapeutics New scaffold for bifunctional molecules with improved properties
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
US12448451B2 (en) 2021-06-25 2025-10-21 Chugai Seiyaku Kabushiki Kaisha Anti-CTLA-4 antibody and use thereof
TWI864408B (zh) 2021-06-25 2024-12-01 日商中外製藥股份有限公司 抗ctla-4抗體的用途
JP7472405B2 (ja) 2021-06-25 2024-04-22 中外製薬株式会社 抗ｃｔｌａ－４抗体
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
JP2025508939A (ja) 2022-03-02 2025-04-10 イミュニティーバイオ インコーポレイテッド 膵臓癌の治療方法
EP4507704A1 (en) 2022-04-15 2025-02-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
WO2024028386A1 (en) 2022-08-02 2024-02-08 Ose Immunotherapeutics Multifunctional molecule directed against cd28
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
JP2025539816A (ja) 2022-11-21 2025-12-09 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の増幅のための２次元プロセス及びそれからの治療法
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024200820A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
WO2024200823A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001054732A1 (en) * 2000-01-27 2001-08-02 Genetics Institute, Llc. Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
US20080279865A1 (en) * 2005-03-23 2008-11-13 Pfizer, Inc., Pfizer Products, Inc. Therapy of Prostate Cancer With Ctla-4 Antibodies and Hormonal Therapy
RU2353384C2 (ru) * 2003-08-04 2009-04-27 Бристол-Маерс Сквибб Компани Способ лечения сердечно-сосудистого заболевания с применением растворимого ctla4
WO2012140627A1 (en) * 2011-04-15 2012-10-18 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
WO2012156018A1 (en) * 2011-05-13 2012-11-22 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
GB9712892D0 (en) 1997-06-20 1997-08-20 Eclagen Ltd Identification of mhc binding peptides
SI2112166T1 (sl) 1998-12-23 2019-05-31 Pfizer Inc. Človeška monoklonska protitelesa proti CTLA-4
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
AU7337400A (en) 1999-09-03 2001-04-10 Human Genome Sciences, Inc. B7-like polynucleotides, polypeptides, and antibodies
SG148022A1 (en) 2000-01-28 2008-12-31 Univ Singapore Novel ligands and methods for preparing same
BR0309254A (pt) * 2002-04-12 2005-03-01 Medarex Inc Uso de um anticorpo anti-ctla-4
CN1898267B (zh) 2003-11-01 2012-05-23 默克专利股份有限公司 修饰的抗cd52抗体
AU2006210724A1 (en) 2005-02-03 2006-08-10 Antitope Limited Human antibodies and proteins
RU2009113455A (ru) 2006-10-11 2010-11-20 Антитоуп Лимитед (GB) Базы данных т-клеточных эпитопов

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001054732A1 (en) * 2000-01-27 2001-08-02 Genetics Institute, Llc. Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
RU2353384C2 (ru) * 2003-08-04 2009-04-27 Бристол-Маерс Сквибб Компани Способ лечения сердечно-сосудистого заболевания с применением растворимого ctla4
US20080279865A1 (en) * 2005-03-23 2008-11-13 Pfizer, Inc., Pfizer Products, Inc. Therapy of Prostate Cancer With Ctla-4 Antibodies and Hormonal Therapy
WO2012140627A1 (en) * 2011-04-15 2012-10-18 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
WO2012156018A1 (en) * 2011-05-13 2012-11-22 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6

Also Published As

Publication number Publication date
MX344971B (es) 2017-01-12
AU2012224511B2 (en) 2016-09-29
ES2571129T3 (es) 2016-05-24
IL228203A (en) 2017-12-31
RU2013145243A (ru) 2015-04-20
ZA201306589B (en) 2014-05-28
AU2012224511A1 (en) 2013-09-19
KR20140033013A (ko) 2014-03-17
WO2012120125A1 (en) 2012-09-13
JP6211930B2 (ja) 2017-10-11
US9714290B2 (en) 2017-07-25
CA2828528C (en) 2020-04-21
JP2014512809A (ja) 2014-05-29
BR112013022797A2 (pt) 2016-12-06
SG192969A1 (en) 2013-09-30
GB201103955D0 (en) 2011-04-20
CN103547595B (zh) 2017-05-31
EP2683739B1 (en) 2016-03-09
DK2683739T3 (en) 2016-05-23
CA2828528A1 (en) 2012-09-13
CN103547595A (zh) 2014-01-29
MY166776A (en) 2018-07-23
US20140105914A1 (en) 2014-04-17
EP2683739A1 (en) 2014-01-15
MX2013010268A (es) 2014-03-27

Similar Documents

Publication Publication Date Title
RU2629768C2 (ru) Гуманизированные антитела к ctla4
US20230146195A1 (en) Bcma binding molecules and methods of use thereof
RU2605307C2 (ru) Гуманизированные антитела к сd52
US20030232009A1 (en) Anti-CD45RB antibodies for use in treating autoimmune disease and transplant rejection
JP7635401B2 (ja) 抗ｔｎｆｒ２ヒト化抗体及びその使用
JP7264337B2 (ja) 抗ｂ７ｓ１ポリペプチドおよびその使用
CN114616245A (zh) 一种抗cd38的抗体及其用途
Hinojosa et al. Construction of a recombinant non-mitogenic anti-human CD3 antibody
JP2024521697A (ja) 抗ｐｄ－１ポリペプチド及びその使用
CN117396511A (zh) 靶向cd47和pd-l1的双特异性抗体及其使用方法
HK40000650A (en) Bcma binding molecules and methods of use thereof
HK1213910B (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof

Legal Events

Date Code Title Description
HE9A Changing address for correspondence with an applicant
HE9A Changing address for correspondence with an applicant